Thymosin alpha 1 directly binds to galectin-1 — a protein that helps tumors evade immunity and grow blood vessels — blocking its cancer-promoting activities in lab experiments.
Novel interactionFirst demonstration that thymosin alpha 1 directly binds and inhibits galectin-1, a protein that helps tumors evade immunity and grow blood vessels
What the researchers found
Researchers discovered a previously unknown interaction between thymosin alpha 1 (Tα1), a thymic immune-modulating peptide, and galectin-1 (Gal-1), a protein involved in cancer progression, immune suppression, and blood vessel formation. Tα1 directly binds to Gal-1 and alters its biological activity in three key ways: it blocks Gal-1's ability to clump red blood cells (hemagglutination), inhibits the formation of new blood vessel structures by endothelial cells, and reduces cancer cell migration in wound healing assays.
Physico-chemical analysis revealed the molecular details of how Tα1 binds to Gal-1, identifying the specific interaction sites. This is the first study to demonstrate this protein-protein interaction, providing a concrete molecular mechanism that helps explain why Tα1 has such wide-ranging effects across different diseases.
Why it matters
Thymosin alpha 1 has been used clinically for decades — particularly for hepatitis B, immune deficiency, and as a vaccine adjuvant — but scientists have struggled to explain how a single peptide can have beneficial effects in so many different conditions. This study identifies a specific molecular target (galectin-1) that could explain much of Tα1's versatility. Since galectin-1 promotes tumor immune evasion, blood vessel growth for tumors, and cancer cell migration, blocking it with Tα1 could be relevant to cancer therapy.
The numbers in context
Tα1 inhibited Gal-1 hemagglutination · blocked endothelial tube formation · reduced cancer cell migration · molecular interaction characterized by NMR and biophysical methods
How the study worked
The study combined molecular biology and biophysical approaches. Hemagglutination assays tested Tα1's ability to block Gal-1's sugar-binding activity. In vitro tube formation assays using endothelial cells assessed anti-angiogenic effects. Wound healing assays measured cancer cell migration. Nuclear magnetic resonance (NMR) spectroscopy and other physico-chemical methods characterized the molecular details of the Tα1-Gal-1 interaction at the structural level.
Who was studied
Not applicable (in vitro study using cell lines and purified proteins)
What this study cannot tell us
All experiments were conducted in vitro (in lab dishes), so the Tα1-Gal-1 interaction and its functional consequences have not been confirmed in living organisms. The concentrations of Tα1 used in the assays may not reflect physiological or therapeutic levels. The study does not determine whether this interaction is the primary mechanism of Tα1's clinical effects or one of several. Cancer cell migration was tested in a simplified wound healing assay that doesn't capture the full complexity of metastasis.
How to read the evidence
This is a basic science study using in vitro methods to identify a novel protein-protein interaction. While the molecular characterization is rigorous (including NMR confirmation), all findings are from lab experiments without in vivo validation. The 'Preliminary' grade reflects the early-stage nature of this mechanistic discovery.
When this study was published
Published in 2023, this is a recent finding that adds to the growing understanding of thymosin alpha 1's mechanisms. As a novel discovery, it has had limited time for independent replication or follow-up studies.
The bigger picture
Thymosin alpha 1 is approved in over 30 countries for various immune-related conditions, but its mechanism of action has been poorly understood. Identifying galectin-1 as a direct target is significant because galectin-1 is overexpressed in many cancers and is actively being pursued as a therapeutic target by other research groups. This finding creates a bridge between thymosin alpha 1 research and the broader galectin biology field.
Questions still open
- Does the Tα1-Gal-1 interaction occur at clinically relevant concentrations in patients receiving thymosin alpha 1 therapy?
- Could thymosin alpha 1 enhance the effectiveness of cancer immunotherapy by blocking galectin-1's immune-suppressive effects?
- Is galectin-1 inhibition the primary mechanism behind thymosin alpha 1's clinical benefits, or is it one of many?
Common questions
What is galectin-1 and why does it matter in cancer?
Does this mean thymosin alpha 1 is a cancer treatment?
Read the original research
Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.
International immunopharmacology, 118, 110113
Citation
Matteucci, Claudia; Nepravishta, Ridvan; Argaw-Denboba, Ayele; Mandaliti, Walter; Giovinazzo, Alessandro; Petrone, Vita; Balestrieri, Emanuela; Sinibaldi-Vallebona, Paola; Pica, Francesca; Paci, Maurizio; Garaci, Enrico. (2023). Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.. International immunopharmacology, 118, 110113. https://doi.org/10.1016/j.intimp.2023.110113